An EQA scheme for antimicrobial susceptibility testing in Neisseria gonorrhoeae has been available to laboratories participating in ECDC’s European Sexually Transmitted Infections (STI) surveillance network since 2010. This is the third EQA to be published on antimicrobial susceptibility testing in Neisseria gonorrhoeae.
The 31st IUSTI (International Union Against Sexually Transmitted Infections) Europe Congress addressed the broad range of science and clinical practice in the field of sexually transmitted infections.
According to test results from the annual European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP), resistance levels to the main antimicrobials used for treatment of gonorrhoea infection have seen an encouraging decrease since 2010.
The European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP) follows a decentralised and centralised testing model. In 2015, 24 EU/EEA Member States participated in Euro-GASP, 17 through decentralised testing.
The surveillance of gonococcal antimicrobial susceptibility surveillance in Europe is essential for detecting emerging and increasing antimicrobial resistance and making quality-assured data available to inform revisions of treatment guidelines. ECDC coordinates the Euro-GASP network.
The XXVIII IUSTI (International Union Against Sexually Transmitted Infections) Europe Congress addressed the broad range of science and clinical practice in the field of sexually transmitted infections and HIV.
An EQA scheme for antimicrobial susceptibility testing of Neisseria gonorrhoeae has been available to laboratories participating in ECDC’s European Sexually Transmitted Infections (STI) surveillance network since 2010. This EQA scheme has so far shown high levels of inter-laboratory comparability in the presence of differing methodologies.